Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/5262
Full metadata record
DC FieldValueLanguage
dc.contributor.authorColeman, Julie L-
dc.contributor.authorHatch-McChesney, Adrienne-
dc.contributor.authorSmall, Stephanie D-
dc.contributor.authorAllen, Jillian T-
dc.date.accessioned2023-08-02T08:12:15Z-
dc.date.available2023-08-02T08:12:15Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/5262-
dc.description.abstractThe impact of gut microbiota–targeted interventions on the incidence, duration, and severity of respiratory tract infections (RTIs) in nonelderly adults, and factors moderating any such effects, are unclear. This systematic review and meta-analysis aimed to determine the effects of orally ingested probiotics, prebiotics, and synbiotics compared with placebo on RTI incidence, duration, and severity in nonelderly adults, and to identify potential sources of heterogeneity. Studies were identified by searching CENTRAL, PubMed, Scopus, and Web of Science up to December 2021. English-language, peer-reviewed publications of randomized, placebo-controlled studies that tested an orally ingested probiotic, prebiotic, or synbiotic intervention of any dose for ≥1 wk in adults aged 18–65 y were included. Results were synthesized using intention-to-treat and perprotocol random-effects meta-analysis. Heterogeneity was explored by subgroup meta-analysis and meta-regression. Risk of bias was assessed using the Cochrane risk-of-bias assessment tool for randomized trials version 2 (RoB2). Forty-two manuscripts reporting effects of probiotics (n = 38), prebiotics (n = 2), synbiotics (n = 1) or multiple -biotic types (n = 1) were identified (n = 9179 subjects). Probiotics reduced the risk of experiencing ≥1 RTI (relative risk = 0.91; 95% CI: 0.84, 0.98; P = 0.01), and total days (rate ratio = 0.77; 95% CI: 0.71, 0.83; P < 0.001), duration (Hedges’ g = −0.23; 95% CI: −0.39, −0.08; P = 0.004), and severity (Hedges’ g = −0.16; 95% CI: −0.29, −0.03; P = 0.02) of RTIs. Effects were relatively consistent across different strain combinations, doses, and durations, although reductions in RTI duration were larger with fermented dairy as the delivery matrix, and beneficial effects of probiotics were not observed in physically active populations. Overall risk of bias was rated as “some concerns” for most studies. In conclusion, orally ingested probiotics, relative to placebo, modestly reduce the incidence, duration, and severity of RTIs in nonelderly adults. Physical activity and delivery matrix may moderate some of these effects. Whether prebiotic and synbiotic interventions confer similar protection remains unclear due to few relevant studies. This trial was registered at https://www.crd.york.ac.uk/prospero/ as CRD42020220213en_US
dc.language.isoen_USen_US
dc.subjectrespiratory infectionen_US
dc.subjectrespiratory illnessen_US
dc.subjectcommon colden_US
dc.subjectinfluenzaen_US
dc.subjectcoronavirusen_US
dc.subjectgut microbiomeen_US
dc.subjectfermentable fiberen_US
dc.subjectdietary supplementen_US
dc.titleOrally Ingested Probiotics, Prebiotics, and Synbiotics as Countermeasures for Respiratory Tract Infections in Nonelderly Adults: A Systematic Review and Meta-Analysisen_US
dc.typeArticleen_US
Appears in Collections:VOL 13 NO 6 2022

Files in This Item:
File Description SizeFormat 
2277-2295.pdf777.52 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.